Table 2 Comparison of overall survival benefits among patients with different etiologies of HCC who received anti-PD-1/ anti-PDL1 based therapy
From: Translational research on drug development and biomarker discovery for hepatocellular carcinoma
Etiology | Study | OS hazard ratio (95% CI) | No of subjects ICI-based therapy/Control | |
|---|---|---|---|---|
Non-viral | IMbrave 150 | 0.91 (0.52–1.59) | 100 | 53 |
KEYNOTE-240 | 0.88 (0.64–1.21) | 163 | 85 | |
CheckMate-459 | 0.95 (0.74–1.22) | 168 | 168 | |
RATIONALE-301 | 0.78 (0.55–1.12) | 82 | 80 | |
COSMIC-312 | 1.18 (0.78–1.79) | 169 | 86 | |
LEAP-002 | 0.86 (0.66–1.13) | 118 | 133 | |
Camrelizumab + rivoceranib, 2022 | 0.65 (0.36–1.20) | 42 | 45 | |
HIMALAYA | 0.74 (0.67–0.95) | 161 | 166 | |
HCV-HCC | IMbrave 150 | 0.43 (0.21–0.87) | 72 | 36 |
KEYNOTE-240 | 0.96 (0.48–1.92) | 43 | 21 | |
CheckMate-459 | 0.71 (0.49–1.01) | 87 | 86 | |
RATIONALE-301 | 0.64 (0.38–1.08) | 46 | 39 | |
COSMIC-312 | 1.10 (0.72–1.68) | 136 | 67 | |
LEAP-002 | 0.86 (0.60–1.24) | 94 | 87 | |
Camrelizumab + rivoceranib, 2022 | 0.56 (0.22–1.45) | 22 | 29 | |
HIMALAYA | 1.06 (0.76–1.49) | 110 | 104 | |
HBV-HCC | IMbrave 150 | 0.51 (0.32–0.81) | 164 | 76 |
KEYNOTE-240 | 0.57 (0.35–0.93) | 72 | 29 | |
CheckMate-459 | 0.77 (0.56–1.05) | 116 | 117 | |
RATIONALE-301 | 0.91 (0.73–1.14) | 214 | 213 | |
COSMIC-312 | 0.53 (0.33–0.87) | 127 | 64 | |
LEAP-002 | 0.75 (0.58–0.97) | 192 | 193 | |
Camrelizumab + rivoceranib, 2022 | 0.53 (0.41–0.68) | 208 | 197 | |
HIMALAYA | 0.64 (0.48–0.86) | 122 | 119 | |